Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
- PMID: 38736011
- DOI: 10.1007/s00345-024-05025-x
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
Comment on
-
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.World J Urol. 2024 Mar 2;42(1):113. doi: 10.1007/s00345-024-04799-4. World J Urol. 2024. PMID: 38431689 Clinical Trial.
References
-
- Wada N, Mizunaga M, Abe N et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42:113. https://doi.org/10.1007/s00345-024-04799-4 - DOI - PubMed
-
- Farag F, Sakalis VI, Arteaga SM et al (2023) What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the european association of urology, female non-neurogenic lower urinary tract symptoms guidelines panel. Eur Urol 84:302–312. https://doi.org/10.1016/j.eururo.2023.05.014 - DOI - PubMed
-
- Tarcan T, Selai C, Herve F et al (2020) Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: ICI-RS 2019? Neurourol Urodyn 39:S70–S79. https://doi.org/10.1002/nau.24361 - DOI - PubMed
-
- Kinjo M, Masuda K, Nakamura Y et al (2023) Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175:67–73. https://doi.org/10.1016/j.urology.2023.02.003 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical